ArticleJournal of controlled release : official journal of the Controlled Release Society2012
Alkane-modified short polyethyleneimine for siRNA delivery.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Nanotechnology-based mRNA vaccines.Nature reviews. Methods primers · 2023Article
- Toward the prevention of coronavirus infection: what role can polymers play?Materials today. Advances · 2021Review
- Recent advances of sorafenib nanoformulations for cancer therapy: Smart nanosystem and combination therapy.Asian journal of pharmaceutical sciences · 2021Review
- PEI fluorination reduces toxicity and promotes liver-targeted siRNA delivery.Drug delivery and translational research · 2021Article
- Strategies, design, and chemistry in siRNA delivery systems.Advanced drug delivery reviews · 2019Review
- Cytosolic delivery of siRNA by ultra-high affinity dsRNA binding proteins.Nucleic acids research · 2017Article
- Screening of efficient siRNA carriers in a library of surface-engineered dendrimers.Scientific reports · 2016Article
- Micelle-like nanoparticles as carriers for DNA and siRNA.Molecular pharmaceutics · 2015Review
- Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid Tumors.Journal of pharmaceutical innovation · 2014Article
- Phospholipid-modified polyethylenimine-based nanopreparations for siRNA-mediated gene silencing: implications for transfection and the role of lipid components.Nanomedicine : nanotechnology, biology, and medicine · 2014Article
- Degradable terpolymers with alkyl side chains demonstrate enhanced gene delivery potency and nanoparticle stability.Advanced materials (Deerfield Beach, Fla.) · 2013Article
- In vitro-in vivo translation of lipid nanoparticles for hepatocellular siRNA delivery.ACS nano · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
RNA interference (RNAi) is a highly specific gene-silencing mechanism triggered by small interfering RNA (siRNA). Effective intracellular delivery requires the development of potent siRNA carriers. Here, we describe the synthesis and screening of a series of siRNA delivery materials. Short polyethyleneimine (PEI, Mw 600) was selected as a cationic backbone to which lipid tails were conjugated at various levels of saturation. In solution these polymer-lipid hybrids self-assemble to form nanoparticles capable of complexing siRNA. The complexes silence genes specifically and with low cytotoxicity. The efficiency of gene knockdown increased as the number of lipid tails conjugated to the PEI backbone increased. This is explained by reducing the binding affinity between the siRNA strands to the complex, thereby enabling siRNA release after cellular internalization. These results highlight the importance of complexation strength when designing siRNA delivery materials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.